Consensus CONMED Corporation

Stocks

CNMD

US2074101013

Medical Equipment, Supplies & Distribution

Market Closed - NYSE Other stock markets 01:30:02 27/06/2026 am IST			5-day change	1st Jan Change
35.95 ^USD	+4.02%		+10.34%	-11.45%

18/06	CONMED Names Former Certara CFO John Gallagher as Finance Chief	MT
18/06	CONMED Corporation Appoints John E. Gallagher as Executive Vice President, Principal Financial Officer and Principal Accounting Officer, Effective July 15, 2026	CI

Evolution of the Average Target: CONMED Corporation

Evolution of the Target Price: CONMED Corporation

Changes in Analyst Recommendations: CONMED Corporation

aa9f1de472a4bd99ca685dca109b09.PUftcB_LMEVUF9f5e3eMSDS9g3TRSUUa6DF_ytZpbEg.czaCNiufdCEWWaCRKUTeDgz38zaXOik3hn02maUZHj9zcI4oLah8HzNP7w~872548549853e04fca6c6a6a8cb281e7

Analysts' recommendations: CONMED Corporation

18/05	BofA Securities Adjusts CONMED Price Target to $40 From $52	MT
17/03	Piper Sandler Downgrades CONMED to Neutral From Overweight, Adjusts PT to $39 From $55	MT
12/25/12	Conmed Shares Fall After Needham Downgrade	MT
12/25/12	Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target	MT
28/25/28	Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75	MT
06/25/06	JPMorgan Downgrades CONMED to Neutral From Overweight, Adjusts Price Target to $70 From $85	MT
01/24/01	Needham Adjusts CONMED's Price Target to $97 From $106, Keeps Buy Rating	MT
25/24/25	Needham Trims Price Target on CONMED to $106 From $107, Keeps Buy Rating	MT
25/24/25	Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating	MT
25/24/25	Needham Lowers Price Target on CONMED to $107 From $129, Notes Slight Guidance Cut Due to Currency, Keeps Buy Rating	MT
01/24/01	Needham Adjusts Price Target on CONMED to $129 From $119, Maintains Buy Rating	MT
01/24/01	JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating	MT
27/23/27	Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating	MT
26/23/26	Wells Fargo Cuts Price Target on CONMED to $107 From $123, Maintains Equalweight Rating	MT
27/23/27	Needham Adjusts Price Target on CONMED to $140 From $139, Maintains Buy Rating	MT
27/23/27	Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating	MT
05/23/05	Needham Raises Price Target on CONMED to $139 From $135, Keeps Buy Rating	MT
22/23/22	CL King Starts CONMED at Buy With $140 Price Target	MT
27/23/27	Piper Sandler Raises CONMED's Price Target to $128 From $118, Maintains Overweight Rating	MT
27/23/27	Wells Fargo Adjusts Price Target on CONMED to $119 From $96, Maintains Equal-Weight Rating	MT
27/23/27	Needham Adjusts Price Target on CONMED to $135 From $122, Reiterates Buy Rating	MT
27/23/27	Keybanc Adjusts Price Target on CONMED to $131 From $124, Maintains Overweight Rating	MT
27/23/27	CONMED Upgraded by KeyBanc to Overweight From Sector Weight, Price Target Set at $124; Firm Sees Financial Profile Improving	MT
27/23/27	Analyst recommendations: Caterpillar, Conmed, Corning, Model N, United Rentals...
03/23/03	Needham Raises Price Target on CONMED to $122 From $106, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
CONMED CORPORATION	-	+10.15%
ABBOTT LABORATORIES		+23.82%
MEDTRONIC PLC		+21.02%
CENCORA, INC.		+22.67%
HOYA CORPORATION		+18.79%
BECTON, DICKINSON AND COMPANY		+14%
MEDLINE INC.		+31.59%
DEXCOM, INC.		+21.53%
WEST PHARMACEUTICAL SERVICES, INC.		+2.26%
STERIS PLC		+19.1%
Average		+18.49%
Weighted average by Cap.		+20.97%